Studies in healthy humans and patients with lipodystrophy examining hepatic VLDL secretion will also provide key evidence for a potential utility of recombinant leptin as a novel drug for treating obesity-related NAFLD, for which no clinically effective therapy is yet available. The gene discussed is LEP; the disease is Obesity.